Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,803,440.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $450.86, for a total value of $1,803,440.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $58,611.80. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

Shares of UTHR opened at $440.00 on Friday. The stock has a 50 day moving average price of $372.27 and a two-hundred day moving average price of $323.58. The firm has a market capitalization of $19.85 billion, a P/E ratio of 17.17, a P/E/G ratio of 6.79 and a beta of 0.66. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm posted $5.85 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. UMB Bank n.a. lifted its stake in United Therapeutics by 17.1% in the first quarter. UMB Bank n.a. now owns 1,289 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 188 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in United Therapeutics by 20.3% in the first quarter. Farther Finance Advisors LLC now owns 456 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 77 shares during the last quarter. Signet Financial Management LLC lifted its stake in United Therapeutics by 0.7% in the first quarter. Signet Financial Management LLC now owns 10,895 shares of the biotechnology company’s stock valued at $3,359,000 after purchasing an additional 79 shares during the last quarter. SG Americas Securities LLC lifted its stake in United Therapeutics by 210.9% in the first quarter. SG Americas Securities LLC now owns 10,085 shares of the biotechnology company’s stock valued at $3,109,000 after purchasing an additional 6,841 shares during the last quarter. Finally, Nepsis Inc. lifted its stake in United Therapeutics by 6.7% in the first quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company’s stock valued at $18,057,000 after purchasing an additional 3,653 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on UTHR. Bank of America boosted their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Wells Fargo & Company boosted their target price on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research note on Wednesday, September 3rd. Finally, JPMorgan Chase & Co. cut their target price on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Ten research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $457.21.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.